Journal of Case Reports and Reviews in Medicine (ISSN: 3069-0749)
Case Report Volume: 2 & Issue: 4
Case Report Volume: 2 & Issue: 4
Statin intolerance represents a significant clinical challenge in cardiovascular disease prevention, often leading to therapy discontinuation and uncontrolled lipid levels. Monacolin K-free nutraceuticals provide an alternative therapeutic strategy for lipid and glucose management without statin-related side effects. We report the case of a 58-year-old male with moderate hypercholesterolemia, impaired fasting glucose, and a history of statin-associated muscle symptoms (SAMS). After discontinuing statin therapy due to severe myalgia and elevated creatine kinase levels, the patient was started on a daily oral formulation of LopiGLIK® BIO — a nutraceutical containing Trigonella foenum-graecum (fenugreek), Morus alba, and Niacin. After 12 weeks of treatment, the patient showed a significant improvement in lipid levels, with a 22% reduction in low-density lipoprotein cholesterol (LDL-C) and a 19% reduction in total cholesterol, along with stabilized fasting plasma glucose, without experiencing any muscular or gastrointestinal adverse effects. This case highlights the clinical utility and safety of a monacolin K-free nutraceutical combination in managing cardiovascular risk in statin-intolerant patients.
Keywords: Statin Intolerance; Dyslipidemia; LopiGLIK BIO; Nutraceuticals; Fenugreek; Morus alba; Monacolin K-free.
Experiences from authors who have published with SCIVOLVE.